The Reimbursement Committee, which advises the the Danish Medicines Agency on drug reimbursements, has proposed a reassessment of the drug Fiasp, and the company behind the product, Novo Nordisk, has voiced its opposition to the change.
The committee proposes that the fast-acting insulin should receive conditional reimbursement as opposed to a general reimbursement, which would mean that a smaller group of patients would have access to the drug.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.